Diabetes and cancer

Endocrine-Related Cancer

Volumn 16, Issue 4, 2009, Pages 1103-1123

  Vigneri, Paolo ^a   Frasca, Francesco ^a   Sciacca, Laura ^a   Pandini, Giuseppe ^a   Vigneri, Riccardo ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 4 [2 (4 AMINO 1,2,5 OXADIAZOL 3 YL) 1 ETHYL 7 (3 PIPERIDINYLMETHOXY) 1H IMIDAZO[4,5 C]PYRIDIN 4 YL] 2 METHYL 3 BUTYN 2 OL; ABELSON KINASE INHIBITOR; ALPHA GLUCOSIDASE INHIBITOR; EVEROLIMUS; GLITAZONE DERIVATIVE; GLUCOCORTICOID; INSULIN RECEPTOR; MEGLITINIDE; METFORMIN; PERIFOSINE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; SOMATOMEDIN C; SULFONYLUREA; TEMSIROLIMUS; TRICIRIBINE; UNCLASSIFIED DRUG; WORTMANNIN;

BLADDER CANCER; BREAST CANCER; CANCER GROWTH; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CHRONIC INFLAMMATION; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE DURATION; DRUG MEGADOSE; DRUG TARGETING; FATTY ACID BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; KIDNEY CANCER; LIVER CANCER; MALIGNANT NEOPLASTIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHODGKIN LYMPHOMA; OBESITY; OVARY CANCER; OXIDATIVE STRESS; PANCREAS CANCER; PREVALENCE; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; TUMOR LOCALIZATION;

DIABETES COMPLICATIONS; HUMANS; NEOPLASMS; RISK FACTORS; SURVIVAL RATE;

EID: 72549116243     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1677/ERC-09-0087     Document Type: Review

References (138)

1. Adami HO & Trichopoulos D 2003 Obesity and mortality from cancer. New England Journal of Medicine 348 1623-1624.
2. Aguirre D, Boya P, Bellet D, Faivre S, Troalen F, Benard J, Saulnier P, Hopkins-Donaldson S, Zangemeister-Wittke U, Kroemer G et al. 2004 Bcl-2 and CCND1/CDK4 expression levels predict the cellular effects of mTOR inhibitors in human ovarian carcinoma. Apoptosis 9 797-805. (Pubitemid 40941208)
3. Aiello A, Pandini G, Frasca F, Conte E, Murabito A, Sacco A, Genua M, Vigneri R & Belfiore A 2006 Peroxisomal proliferator-activated receptor-gamma agonists induce partial reversion of epithelial-mesenchymal transition in anaplastic thyroid cancer cells. Endocrinology 147 4463-4475. (Pubitemid 44268398)
4. Alimova IN, Liu B, Fan Z, Edgerton SM, Dillon T, Lind SE & Thor AD 2009 Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle 8 909-915.
5. Barone BB, Yeh HC, Snyder CF, Peairs KS, Stein KB, Derr RL, Wolff AC & Brancati FL 2008 Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. Journal of the American Medical Association 300 2754-2764.
6. Barrett-Connor E 1992 Lower endogenous androgen levels and dyslipidemia in men with non-insulin-dependent diabetes mellitus. Annals of Internal Medicine 117 807-811.
7. Basso D, Valerio A, Seraglia R, Mazza S, Piva MG, Greco E, Fogar P, Gallo N, Pedrazzoli S, Tiengo A et al. 2002 Putative pancreatic cancer-associated diabetogenic factor: 2030 MW peptide. Pancreas 24 8-14. (Pubitemid 34019654)
8. Bellmunt J, Szczylik C, Feingold J, Strahs A & Berkenblit A 2008 Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Annals of Oncology 19 1387-1392.
9. Betancourt-Albrecht M & Cunningham GR 2003 Hypogonadism and diabetes. International Journal of Impotence Research 15 S14-S20.
10. Bjornsti MA&Houghton PJ 2004 The TOR pathway: a target for cancer therapy. Nature Reviews. Cancer 4 335-348. (Pubitemid 38579480)
11. Bonovas S, Filioussi K & Tsantes A 2004 Diabetes mellitus and risk of prostate cancer: a meta-analysis. Diabetologia 47 1071-1078. (Pubitemid 38918167)
12. Bowker SL, Majumdar SR, Veugelers P & Johnson JA 2006 Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29 254-258. (Pubitemid 44106500)
13. Buzzetti R, Di Pietro S, Giaccari A, Petrone A, Locatelli M, Suraci C, Capizzi M, Arpi ML, Bazzigaluppi E, Dotta F et al. 2007 High titer of autoantibodies to GAD identifies a specific phenotype of adult-onset autoimmune diabetes. Diabetes Care 30 932-938. (Pubitemid 46556589)
14. Caldwell S & Lazo M 2009 Is exercise an effective treatment for NASH? Knowns and unknowns Annals of Hepatology 8 S60-S66.
15. Calle EE, Rodriguez C, Walker-Thurmond K & Thun MJ 2003 Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. New England Journal of Medicine 348 1625-1638. (Pubitemid 36459468)
16. Cazzaniga M, Bonanni B, Guerrieri-Gonzaga A & Decensi A 2009 Is it time to test metformin in breast cancer clinical trials? Cancer Epidemiology, Biomarkers and Prevention 18 701-705.
17. Cebioglu M, Schild HH & Golubnitschaja O 2008 Diabetes mellitus as a risk factor for cancer: stress or viral etiology? Infectious Disorders - Drug Targets 8 76-87.
18. Chari ST, Leibson CL, Rabe KG, Ransom J, de Andrade M & Petersen GM 2005 Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology 129 504-511. (Pubitemid 41096638)
19. Chari ST, Leibson CL, Rabe KG, Timmons LJ, Ransom J, de Andrade M & Petersen GM 2008 Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology 134 95-101. (Pubitemid 350309328)
20. Chen HF, Li CY, Chen P, See TT & Lee HY 2006 Seroprevalence of hepatitis B and C in type 2 diabetic patients. Journal of the Chinese Medical Association 69 146-152.
21. Chow WH, Gridley G, Fraumeni JF Jr & Jarvholm B 2000 Obesity, hypertension, and the risk of kidney cancer in men. New England Journal of Medicine 343 1305-1311. (Pubitemid 30808125)
22. Claycombe KJ, Jones BH, Standridge MK, Guo Y, Chun JT, Taylor JW & Moustaid-Moussa N 1998 Insulin increases fatty acid synthase gene transcription in human adipocytes. American Journal of Physiology 274 R1253-R1259.
23. Cleary MP & Grossmann ME 2009 Minireview: obesity and breast cancer: the estrogen connection. Endocrinology 150 2537-2542.
24. Cleary MP, Ray A, Rogozina OP, Dogan S & Grossmann ME 2009 Targeting the adiponectin:leptin ratio for postmenopausal breast cancer prevention. Frontiers in Bioscience 1 329-357.
25. Corbould A, Zhao H, Mirzoeva S, Aird F & Dunaif A 2006 Enhanced mitogenic signaling in skeletal muscle of women with polycystic ovary syndrome. Diabetes 55 751-759. (Pubitemid 43343232)
26. Coughlin SS, Calle EE, Teras LR, Petrelli J & Thun MJ 2004 Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. American Journal of Epidemiology 159 1160-1167. (Pubitemid 38747263)
27. Crouthamel MC, Kahana JA, Korenchuk S, Zhang SY, Sundaresan G, Eberwein DJ, Brown KK & Kumar R 2009 Mechanism and management of AKT inhibitor-induced hyperglycemia. Clinical Cancer Research 15 217-225.
28. Dankner R, Chetrit A & Segal P 2007 Glucose tolerance status and 20 year cancer incidence. Israel Medical Association Journal 9 592-596. (Pubitemid 47323414)
29. Davila JA, Morgan RO, Shaib Y, McGlynn KA & El-Serag HB 2005 Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case-control study. Gut 54 533-539. (Pubitemid 40403031)
30. De Block CE, De Leeuw IH & Van Gaal LF 1999 High prevalence of manifestations of gastric autoimmunity in parietal cell antibody-positive type 1 (insulin-dependent) diabetic patients. The Belgian Diabetes Registry. Journal of Clinical Endocrinology and Metabolism 84 4062-4067.
31. De Meyts P, Christoffersen CT, Urso B, Wallach B, Gronskov K, Yakushiji F & Shymko RM 1995 Role of the time factor in signaling specificity: application to mitogenic and metabolic signaling by the insulin and insulin-like growth factor-I receptor tyrosine kinases. Metabolism 44 2-11.
32. Deremer DL, Ustun C & Natarajan K 2008 Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. Clinical Therapeutics 30 1956-1975.
33. Eisen HJ, Tuzcu EM, Dorent R, Kobashigawa J, Mancini D, Valantine-von Kaeppler HA, Starling RC, Sorensen K, Hummel M, Lind JM et al. 2003 Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. New England Journal of Medicine 349 847-858. (Pubitemid 37025404)
34. El-Serag HB, Hampel H & Javadi F 2006 The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clinical Gastroenterology and Hepatology 4 369-380. (Pubitemid 43343895)
35. Elwing JE, Gao F, Davidson NO & Early DS 2006 Type 2 diabetes mellitus: the impact on colorectal adenoma risk in women. American Journal of Gastroenterology 101 1866-1871. (Pubitemid 44166599)
36. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR & Morris AD 2005 Metformin and reduced risk of cancer in diabetic patients. BMJ 330 1304-1305. (Pubitemid 40813563)
37. Everhart J & Wright D 1995 Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. Journal of the American Medical Association 273 1605-1609.
38. Federico A, Morgillo F, Tuccillo C, Ciardiello F & Loguercio C 2007 Chronic inflammation and oxidative stress in human carcinogenesis. International Journal of Cancer 121 2381-2386. (Pubitemid 350022406)
39. Fernandez AM, Kim JK, Yakar S, Dupont J, Hernandez-Sanchez C, Castle AL, Filmore J, Shulman GI & Le Roith D 2001 Functional inactivation of the IGF-I and insulin receptors in skeletal muscle causes type 2 diabetes. Genes and Development 15 1926-1934. (Pubitemid 32738622)
40. Ferrannini E & Cobelli C 1987 The kinetics of insulin in man. II. Role of the liver. Diabetes/Metabolism Reviews 3 365-397.
41. Folsom AR, Anderson KE, Sweeney C & Jacobs DR Jr 2004 Diabetes as a risk factor for death following endometrial cancer. Gynecologic Oncology 94 740-745. (Pubitemid 39194469)
42. Frasca F, Pandini G, Scalia P, Sciacca L, Mineo R, Costantino A, Goldfine ID, Belfiore A & Vigneri R 1999 Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Molecular and Cellular Biology 19 3278-3288. (Pubitemid 29193789)
43. Frasca F, Pandini G, Malaguarnera R, Mandarino A, Messina RL, Sciacca L, Belfiore A & Vigneri R 2007 Role of c-Abl in directing metabolic versus mitogenic effects in insulin receptor signaling. Journal of Biological Chemistry 282 26077-26088. (Pubitemid 47443802)
44. Friberg E, Orsini N, Mantzoros CS & Wolk A 2007 Diabetes mellitus and risk of endometrial cancer: a meta-analysis. Diabetologia 50 1365-1374. (Pubitemid 46879010)
45. Gable KL, Maddux BA, Penaranda C, Zavodovskaya M, Campbell MJ, Lobo M, Robinson L, Schow S, Kerner JA, Goldfine ID et al. 2006 Diarylureas are small-molecule inhibitors of insulin-like growth factor I receptor signaling and breast cancer cell growth. Molecular Cancer Therapeutics 5 1079-1086. (Pubitemid 43724609)
46. Gapstur SM, Gann PH, Lowe W, Liu K, Colangelo L & Dyer A 2000 Abnormal glucose metabolism and pancreatic cancer mortality. Journal of the American Medical Association 283 2552-2558. (Pubitemid 30324198)
47. Genua M, Pandini G, Cassarino MF, Messina RL & Frasca F 2009 Chapter 4 c-Abl and insulin receptor signalling. Vitamins and Hormones 80 77-105.
48. Glass AG, Lacey JV Jr, Carreon JD & Hoover RN 2007 Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. Journal of the National Cancer Institute 99 1152-1161. (Pubitemid 47233065)
49. Goodwin PJ, Ennis M, Fantus IG, Pritchard KI, Trudeau ME, Koo J & Hood N 2005 Is leptin a mediator of adverse prognostic effects of obesity in breast cancer? Journal of Clinical Oncology 23 6037-6042.
50. Govindarajan R, Ratnasinghe L, Simmons DL, Siegel ER, Midathada MV, Kim L, Kim PJ, Owens RJ & Lang NP 2007 Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. Journal of Clinical Oncology 25 1476-1481. (Pubitemid 46733074)
51. Green A & Jensen OM 1985 Frequency of cancer among insulin-treated diabetic patients in Denmark. Diabetologia 28 128-130. (Pubitemid 15102181)
52. Haluska P, Carboni JM, Loegering DA, Lee FY, Wittman M, Saulnier MG, Frennesson DB, Kalli KR, Conover CA, Attar RM et al. 2006 In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417. Cancer Research 66 362-371.
53. Haluska P, Shaw HM, Batzel GN, Yin D, Molina JR, Molife LR, Yap TA, Roberts ML, Sharma A, Gualberto A et al. 2007 Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clinical Cancer Research 13 5834-5840. (Pubitemid 47583908)
54. Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR, Wiedmeyer HM & Byrd-Holt DD 1998 Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 21 518-524.
55. Heuson JC & Legros N 1972 Influence of insulin deprivation on growth of the 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in rats subjected to alloxan diabetes and food restriction. Cancer Research 32 226-232.
56. Heuson JC, Legros N & Heimann R 1972 Influence of insulin administration on growth of the 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in intact, oophorectomized, and hypophysectomized rats. Cancer Research 32 233-238.
57. Hillgartner FB, Salati LM & Goodridge AG 1995 Physiological and molecular mechanisms involved in nutritional regulation of fatty acid synthesis. Physiological Reviews 75 47-76.
58. Hofmann F & Garcia-Echeverria C 2005 Blocking the insulin-like growth factor-I receptor as a strategy for targeting cancer. Drug Discovery Today 10 1041-1047. (Pubitemid 41074142)
59. Hu X, Juneja SC, Maihle NJ & Cleary MP 2002 Leptin - a growth factor in normal and malignant breast cells and for normal mammary gland development. Journal of the National Cancer Institute 94 1704-1711. (Pubitemid 35446839)
60. Hudgins LC 2000 Effect of high-carbohydrate feeding on triglyceride and saturated fatty acid synthesis. Proceedings of the Society for Experimental Biology and Medicine 225 178-183. (Pubitemid 32041496)
61. Hudgins LC, Hellerstein MK, Seidman CE, Neese RA, Tremaroli JD & Hirsch J 2000 Relationship between carbohydrate-induced hypertriglyceridemia and fatty acid synthesis in lean and obese subjects. Journal of Lipid Research 41 595-604. (Pubitemid 30220663)
62. Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, Barzi F & Woodward M 2005 Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. British Journal of Cancer 92 2076-2083. (Pubitemid 40897433)
63. Ihle NT, Williams R, Chow S, Chew W, Berggren MI, Paine-Murrieta G, Minion DJ, Halter RJ, Wipf P, Abraham R et al. 2004 Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling. Molecular Cancer Therapeutics 3 763-772. (Pubitemid 39193758)
64. Ihle NT, Lemos R Jr, Wipf P, Yacoub A, Mitchell C, Siwak D, Mills GB, Dent P, Kirkpatrick DL & Powis G 2009a Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Research 69 143-150.
65. Ihle NT, Lemos R, Schwartz D, Oh J, Halter RJ, Wipf P, Kirkpatrick L & Powis G 2009b Peroxisome proliferator-activated receptor gamma agonist pioglitazone prevents the hyperglycemia caused by phosphatidylinositol 3-kinase pathway inhibition by PX-866 without affecting antitumor activity. Molecular Cancer Therapeutics 8 94-100.
66. Ji QS, Mulvihill MJ, Rosenfeld-Franklin M, Cooke A, Feng L, Mak G, O'Connor M, Yao Y, Pirritt C, Buck E et al. 2007 A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor- I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo. Molecular Cancer Therapeutics 6 2158-2167. (Pubitemid 47294744)
67. Kaaks R 1996 Nutrition, hormones, and breast cancer: is insulin the missing link? Cancer Causes and Control 7 605-625.
68. Kaaks R & Lukanova A 2001 Energy balance and cancer: the role of insulin and insulin-like growth factor-I. Proceedings of the Nutrition Society 60 91-106. (Pubitemid 32183103)
69. Kalli KR, Falowo OI, Bale LK, Zschunke MA, Roche PC & Conover CA 2002 Functional insulin receptors on human epithelial ovarian carcinoma cells: implications for IGF-II mitogenic signaling. Endocrinology 143 3259-3267.
70. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, Tanaka C, Manley P, Rae P, Mietlowski W et al. 2006 Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. New England Journal of Medicine 354 2542-2551. (Pubitemid 43882350)
71. Kasper JS & Giovannucci E 2006 A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiology, Biomarkers and Prevention 15 2056-2062. (Pubitemid 44877026)
72. Kauffman HM, Cherikh WS, Cheng Y, Hanto DW & Kahan BD 2005 Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 80 883-889. (Pubitemid 41552882)
73. Keating NL, O'Malley AJ & Smith MR 2006 Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. Journal of Clinical Oncology 24 4448-4456. (Pubitemid 46630983)
74. Kern PA, Ranganathan S, Li C, Wood L & Ranganathan G 2001 Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. American Journal of Physiology. Endocrinology and Metabolism 280 E745-E751. (Pubitemid 32466842)
75. Key TJ, Appleby PN, Reeves GK, Roddam A, Dorgan JF, Longcope C, Stanczyk FZ, Stephenson HE Jr, Falk RT, Miller R et al. 2003 Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. Journal of the National Cancer Institute 95 1218-1226. (Pubitemid 37069552)
76. Koro C, Barrett S & Qizilbash N 2007 Cancer risks in thiazolidinedione users compared to other anti-diabetic agents. Pharmacoepidemiology and Drug Safety 16 485-492. (Pubitemid 46824269)
77. von Kriegstein E & von Kriegstein K 2007 Inhaled insulin for diabetes mellitus. New England Journal of Medicine 356 2106.
78. Krone CA & Ely JT 2005 Controlling hyperglycemia as an adjunct to cancer therapy. Integrated Cancer Therapy 4 25-31.
79. Kuzuya H, Matsuura N, Sakamoto M, Makino H, Sakamoto Y, Kadowaki T, Suzuki Y, Kobayashi M, Akazawa Y, Nomura M et al. 1993 Trial of insulin-like growth factor I therapy for patients with extreme insulin resistance syndromes. Diabetes 42 696-705. (Pubitemid 23127160)
80. Lacy MQ, Alsina M, Fonseca R, Paccagnella ML, Melvin CL, Yin D, Sharma A, Enriquez Sarano M, Pollak M, Jagannath S et al. 2008 Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 receptor monoclonal antibody CP-751,871 in patients with multiple myeloma. Journal of Clinical Oncology 26 3196-3203.
81. Larsson SC, Orsini N & Wolk A 2005 Diabetes mellitus and risk of colorectal cancer: a meta-analysis. Journal of the National Cancer Institute 97 1679-1687. (Pubitemid 41672234)
82. Larsson SC, Orsini N, Brismar K & Wolk A 2006 Diabetes mellitus and risk of bladder cancer: a meta-analysis. Diabetologia 49 2819-2823. (Pubitemid 44730282)
83. Larsson SC, Mantzoros CS & Wolk A 2007 Diabetes mellitus and risk of breast cancer: a meta-analysis. International Journal of Cancer 121 856-862.
84. Limburg PJ, Vierkant RA, Fredericksen ZS, Leibson CL, Rizza RA, Gupta AK, Ahlquist DA, Melton LJ III, Sellers TA & Cerhan JR 2006 Clinically confirmed type 2 diabetes mellitus and colorectal cancer risk: a population-based, retrospective cohort study. American Journal of Gastroenterology 101 1872-1879. (Pubitemid 44166600)
85. Lindblad P & Adami HO 2002 Kidney cancer. In Textbook of Cancer Epidemiology, pp 467-485. Eds D Hunter, HO Adami & D Trichopoulos. New York: Oxford University Press.
86. Lindblad P, Chow WH, Chan J, Bergstrom A, Wolk A, Gridley G, McLaughlin JK, Nyren O & Adami HO 1999 The role of diabetes mellitus in the aetiology of renal cell cancer. Diabetologia 42 107-112. (Pubitemid 29039747)
87. Lipscombe LL, Goodwin PJ, Zinman B, McLaughlin JR & Hux JE 2008 The impact of diabetes on survival following breast cancer. Breast Cancer Research and Treatment 109 389-395. (Pubitemid 351644852)
88. LoPiccolo J, Blumenthal GM, Bernstein WB & Dennis PA 2008 Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resistance Updates 11 32-50.
89. Lorber MI, Mulgaonkar S, Butt KM, Elkhammas E, Mendez R, Rajagopalan PR, Kahan B, Sollinger H, Li Y, Cretin N et al. 2005 Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study. Transplantation 80 244-252. (Pubitemid 41061682)
90. Luo Z, Saha AK, Xiang X & Ruderman NB 2005 AMPK, the metabolic syndrome and cancer. Trends in Pharmacological Sciences 26 69-76.
91. Lupu R & Menendez JA 2006a Pharmacological inhibitors of fatty acid synthase (FASN) - catalyzed endogenous fatty acid biogenesis: a new family of anti-cancer agents? Current Pharmaceutical Biotechnology 7 483-493.
92. Lupu R & Menendez JA 2006b Targeting fatty acid synthase in breast and endometrial cancer: an alternative to selective estrogen receptor modulators? Endocrinology 147 4056-4066.
93. Ma J, Li H, Giovannucci E, Mucci L, Qiu W, Nguyen PL, Gaziano JM, Pollak M & Stampfer MJ 2008 Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncology 9 1039-1047.
94. Majumder PK, Febbo PG, Bikoff R, Berger R, Xue Q, McMahon LM, Manola J, Brugarolas J, McDonnell TJ, Golub TR et al. 2004 mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nature Medicine 10 594-601. (Pubitemid 38796850)
95. Malizzia LJ & Hsu A 2008 Temsirolimus, an mTOR inhibitor for treatment of patients with advanced renal cell carcinoma. Clinical Journal of Oncology Nursing 12 639-646.
96. McCarty MF 2004 Chronic activation of AMP-activated kinase as a strategy for slowing aging. Medical Hypotheses 63 334-339.
97. Menendez JA, Vazquez-Martin A, Ortega FJ & Fernandez-Real JM 2009 Fatty acid synthase: association with insulin resistance, type 2 diabetes, and cancer. Clinical Chemistry 55 425-438.
98. Meyerhardt JA, Catalano PJ, Haller DG, Mayer RJ, Macdonald JS, Benson AB III & Fuchs CS 2003 Impact of diabetes mellitus on outcomes in patients with colon cancer. Journal of Clinical Oncology 21 433-440. (Pubitemid 46606471)
99. Mitri J & Pittas AG 2009 Inhaled insulin - what went wrong. Nature Clinical Practice. Endocrinology and Metabolism 5 24-25.
100. Mitri J, Castillo J & Pittas AG 2008 Diabetes and risk of non-Hodgkin's lymphoma: a meta-analysis of observational studies. Diabetes Care 31 2391-2397.
101. Moller DE, Yokota A, Caro JF & Flier JS 1989 Tissue-specific expression of two alternatively spliced insulin receptor mRNAs in man. Molecular Endocrinology 3 1263-1269. (Pubitemid 19210437)
102. Monami M, Balzi D, Lamanna C, Barchielli A, Masotti G, Buiatti E, Marchionni N & Mannucci E 2007 Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality Diabetes/Metabolism Research and Reviews 23 479-484.
103. Moustaid N, Jones BH & Taylor JW 1996 Insulin increases lipogenic enzyme activity in human adipocytes in primary culture. Journal of Nutrition 126 865-870. (Pubitemid 26100956)
104. Mulvihill MJ, Ji QS, Coate HR, Cooke A, Dong H, Feng L, Foreman K, Rosenfeld-Franklin M, Honda A, Mak G et al. 2008 Novel 2-phenylquinolin-7-yl- derived imidazo[ 1,5-a]pyrazines as potent insulin-like growth factor-I receptor (IGF-IR) inhibitors. Bioorganic and Medicinal Chemistry 16 1359-1375. (Pubitemid 351191767)
105. Noy A & Bilezikian JP 1994 Clinical review 63: diabetes and pancreatic cancer: clues to the early diagnosis of pancreatic malignancy. Journal of Clinical Endocrinology and Metabolism 79 1223-1231. (Pubitemid 24983170)
106. Ohshima H, Tatemichi M & Sawa T 2003 Chemical basis of inflammation-induced carcinogenesis. Archives of Biochemistry and Biophysics 417 3-11.
107. Oldenburg B, Diepersloot RJ & Hoekstra JB 1996 High seroprevalence of Helicobacter pylori in diabetes mellitus patients. Digestive Diseases and Sciences 41 458-461. (Pubitemid 26116401)
108. Pannala R, Leirness JB, Bamlet WR, Basu A, Petersen GM & Chari ST 2008 Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology 134 981-987.
109. Pannala R, Basu A, Petersen GM & Chari ST 2009 New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. Lancet Oncology 10 88-95.
110. Panwalkar A, Verstovsek S & Giles FJ 2004 Mammalian target of rapamycin inhibition as therapy for hematologic malignancies. Cancer 100 657-666. (Pubitemid 38176841)
111. Papa V, Pezzino V, Costantino A, Belfiore A, Giuffrida D, Frittitta L, Vannelli GB, Brand R, Goldfine ID & Vigneri R 1990 Elevated insulin receptor content in human breast cancer. Journal of Clinical Investigation 86 1503-1510. (Pubitemid 20372597)
112. Pennisi P, Gavrilova O, Setser-Portas J, Jou W, Santopietro S, Clemmons D, Yakar S & LeRoith D 2006 Recombinant human insulin-like growth factor-I treatment inhibits gluconeogenesis in a transgenic mouse model of type 2 diabetes mellitus. Endocrinology 147 2619-2630. (Pubitemid 43764594)
113. Pollak M 2008 Insulin and insulin-like growth factor signalling in neoplasia. Nature Reviews. Cancer 8 915-928.
114. Postic C & Girard J 2008 The role of the lipogenic pathway in the development of hepatic steatosis. Diabetes and Metabolism 34 643-648.
115. Ramos-Nino ME, MacLean CD & Littenberg B 2007 Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information System. BMC Medicine 5 17. (Pubitemid 47226207)
116. Reed MJ & Purohit A 2001 Aromatase regulation and breast cancer. Clinical Endocrinology 54 563-571.
117. Rhodes N, Heerding DA, Duckett DR, Eberwein DJ, Knick VB, Lansing TJ, McConnell RT, Gilmer TM, Zhang SY, Robell K et al. 2008 Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity. Cancer Research 68 2366-2374.
118. del Rincon JP, Iida K, Gaylinn BD, McCurdy CE, Leitner JW, Barbour LA, Kopchick JJ, Friedman JE, Draznin B & Thorner MO 2007 Growth hormone regulation of p85alpha expression and phosphoinositide 3-kinase activity in adipose tissue: mechanism for growth hormone-mediated insulin resistance. Diabetes 56 1638-1646. (Pubitemid 46842597)
119. Ruderman N & Prentki M 2004 AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome. Nature Reviews. Drug Discovery 3 340-351. (Pubitemid 38499761)
120. Saylor PJ & Smith MR 2009 Metabolic complications of androgen deprivation therapy for prostate cancer. Journal of Urology 181 1998-2006.
121. Sciacca L, Costantino A, Pandini G, Mineo R, Frasca F, Scalia P, Sbraccia P, Goldfine ID, Vigneri R & Belfiore A 1999 Insulin receptor activation by IGF-II in breast cancers: evidence for a new autocrine/paracrine mechanism. Oncogene 18 2471-2479. (Pubitemid 29206160)
122. Semenkovich CF, Coleman T & Fiedorek FT Jr 1995 Human fatty acid synthase mRNA: tissue distribution, genetic mapping, and kinetics of decay after glucose deprivation. Journal of Lipid Research 36 1507-1521.
123. Stadler J, Yeung KS, Furrer R, Marcon N, Himal HS & Bruce WR 1988 Proliferative activity of rectal mucosa and soluble fecal bile acids in patients with normal colons and in patients with colonic polyps or cancer. Cancer Letters 38 315-320. (Pubitemid 18060001)
124. Stevens RJ, Roddam AW & Beral V 2007 Pancreatic cancer in type 1 and young-onset diabetes: systematic review and meta-analysis. British Journal of Cancer 96 507-509. (Pubitemid 46215224)
125. Szlosarek P, Charles KA & Balkwill FR 2006 Tumour necrosis factor-alpha as a tumour promoter. European Journal of Cancer 42 745-750.
126. Turturro F, Friday E & Welbourne T 2007 Hyperglycemia regulates thioredoxin-ROS activity through induction of thioredoxin-interacting protein (TXNIP) in metastatic breast cancer-derived cells MDA-MB-231. BMC Cancer 7 96. (Pubitemid 47054112)
127. Vasilcanu R, Vasilcanu D, Rosengren L, Natalishvili N, Sehat B, Yin S, Girnita A, Axelson M, Girnita L & Larsson O 2008 Picropodophyllin induces downregulation of the insulin-like growth factor 1 receptor: potential mechanistic involvement of Mdm2 and β-arrestin1. Oncogene 27 1629-1638. (Pubitemid 351347881)
128. Vella V, Pandini G, Sciacca L, Mineo R, Vigneri R, Pezzino V & Belfiore A 2002 A novel autocrine loop involving IGF-II and the insulin receptor isoform-A stimulates growth of thyroid cancer. Journal of Clinical Endocrinology and Metabolism 87 245-254. (Pubitemid 34084698)
129. Veneri D, Franchini M & Bonora E 2005 Imatinib and regression of type 2 diabetes. New England Journal of Medicine 352 1049-1050.
130. Vigneri P, Frasca F, Sciacca L, Frittitta L & Vigneri R 2006 Obesity and cancer. Nutrition, Metabolism, and Cardiovascular Diseases 16 1-7.
131. Washio M, Mori M, Khan M, Sakauchi F, Watanabe Y, Ozasa K, Hayashi K, Miki T, Nakao M, Mikami K et al. 2007 Diabetes mellitus and kidney cancer risk: the results of Japan Collaborative Cohort Study for Evaluation of Cancer Risk (JACC Study). International Journal of Urology 14 393-397. (Pubitemid 46776217)
132. Will JC, Galuska DA, Vinicor F & Calle EE 1998 Colorectal cancer: another complication of diabetes mellitus? American Journal of Epidemiology 147 816-825.
133. Williams JA & Goldfine ID 1985 The insulin-pancreatic acinar axis. Diabetes 34 980-986.
134. Yakar S, Setser J, Zhao H, Stannard B, Haluzik M, Glatt V, Bouxsein ML, Kopchick JJ & LeRoith D 2004 Inhibition of growth hormone action improves insulin sensitivity in liver IGF-1-deficient mice. Journal of Clinical Investigation 113 96-105. (Pubitemid 38541636)
135. Yuan JM, Castelao JE, Gago-Dominguez M, Ross RK & Yu MC 1998 Hypertension, obesity and their medications in relation to renal cell carcinoma. British Journal of Cancer 77 1508-1513. (Pubitemid 28190754)
136. Zendehdel K, Nyren O, Ostenson CG, Adami HO, Ekbom A & Ye W 2003 Cancer incidence in patients with type 1 diabetes mellitus: a population-based cohort study in Sweden. Journal of the National Cancer Institute 95 1797-1800. (Pubitemid 38008903)
137. Zimmermann K, Wittman MD, Saulnier MG, Velaparthi U, Langley DR, Sang X, Frennesson D, Carboni J, Li A, Greer A et al. 2008 Balancing oral exposure with Cyp3A4 inhibition in benzimidazole-based IGF-IR inhibitors. Bioorganic and Medicinal Chemistry Letters 18 4075-4080.
138. Zucchetto A, Dal Maso L, Tavani A, Montella M, Ramazzotti V, Talamini R, Canzonieri V, Garbeglio A, Negri E, Franceschi S et al. 2007 History of treated hypertension and diabetes mellitus and risk of renal cell cancer. Annals of Oncology 18 596-600. (Pubitemid 46359645)